LRRK2 is a large multidomain protein kinase, and the most prominent pathogenic mutation (G2019S) situated within the kinase domain increases its activity in vitro as well as in vivo, suggesting that LRRK2 inhibitors may be therapeutically beneficial for at least LRRK2-related PD [4,5,6,7,8,9,10,11]. Here, LRRK2 is linked to Parkinson disease.